<DOC>
	<DOC>NCT01547546</DOC>
	<brief_summary>This open-label, multicenter, Phase I, dose-escalating study will evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy of GDC-0084 in patients with progressive or recurrent high-grade glioma. Stage 1 is the dose escalation part of the study. Stage 2, patients will receive GDC-0084 at a recommended dose for future studies.</brief_summary>
	<brief_title>A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Interval of at least 12 weeks from completion of adjuvant radiotherapy for gliomas to study entry Karnofsky Performance Status of &gt;/= 70 at screening Confirmed measurable disease per RANO Adequate hematologic and organ function Patients enrolled in Stage 1: Histologically documented recurrent or progressive highgrade gliomas (WHO Grade IIIIV) Prior treatment with at least one regimen for gliomas (radiotherapy with or without chemotherapy for Grade III gliomas and radiotherapy with chemotherapy for Grade IV gliomas) and/or not considered to be a candidate for regimens known to provide clinical benefit Patients enrolled in Stage 2: Histologically documented recurrent or progressive glioblastoma (WHO Grade IV gliomas) Prior treatment with one or two regimens for glioblastoma (with the initial regimen consisting of radiotherapy with chemotherapy) Treatment with antitumor therapy (approved or experimental) within 4 weeks prior to initiation of study drug Requirement for anticoagulants such as warfarin or any other warfarinderivative anticoagulants; lowmolecularweight heparin is permitted Any contraindication to MRI examination Evidence of Grade &gt;/= 1 intracranial hemorrhage Active congestive heart failure or ventricular arrhythmia requiring medication Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse or cirrhosis Unresolved toxicity from prior therapy with the exception of lymphopenia (for patients with prior temozolomide) and alopecia Pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>